Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climateAnalysts, Analytics, Approvals, August 2018, Biologics, Biosimilars, Blockbusters, Business, Cannabinoids, Dravet syndrome, Epilepsy, EvaluatePharma, FDA/Regulatory, Gastroenterology, GlobalData, Immunological Disorders, Immunology, Immunomodulator Drugs, Innovation, Issue Archives, Lennox-Gastaut Syndrome (LGS), Mantle Cell Lymphoma (MCL), Myelodysplastic Syndromes, Prostate Cancer, Shingles, Special Reports, Therapeutics, Top 200 Medicines, Tumor Necrosis Factor (TNF) Inhibitors, Ulcerative ColitisThere were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015. Read more August 9, 2018/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2016/08/Humira-Pen.jpg 151 300 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2018-08-09 04:09:342020-10-12 15:56:50Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate